Cellectis S.A. (CLLS)

NASDAQ: CLLS · IEX Real-Time Price · USD
2.21
-0.03 (-1.34%)
Dec 9, 2022 4:30 PM EST - Market closed
-1.34%
Market Cap 109.53M
Revenue (ttm) 22.18M
Net Income (ttm) -104.32M
Shares Out 45.48M
EPS (ttm) -2.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 33,426
Open 2.25
Previous Close 2.24
Day's Range 2.21 - 2.25
52-Week Range 2 - 9.3
Beta 1.87
Analysts Buy
Price Target 23.99 (+985.5%)
Earnings Date Nov 3, 2022

About CLLS

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 ... [Read more]

Industry Biotechnology
IPO Date Feb 7, 2007
CEO Andre Choulika
Employees 294
Stock Exchange NASDAQ
Ticker Symbol CLLS
Full Company Profile

Financial Performance

In 2021, Cellectis's revenue was 67.07 million, a decrease of -18.66% compared to the previous year's 82.46 million. Losses were -114.20 million, 40.9% more than in 2020.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for CLLS stock is "Buy." The 12-month stock price forecast is 23.99, which is an increase of 985.52% from the latest price.

Price Target
$23.99
(985.52% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to devel...

1 week ago - GlobeNewsWire

Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid ...

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to devel...

4 weeks ago - GlobeNewsWire

Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex ...

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to devel...

4 weeks ago - GlobeNewsWire

Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022

NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop potentially li...

1 month ago - GlobeNewsWire

Cellectis to Report Third Quarter 2022 Financial Results

NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving ce...

1 month ago - GlobeNewsWire

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease a...

NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develo...

1 month ago - GlobeNewsWire

Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting a...

NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develo...

2 months ago - GlobeNewsWire

Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer

NEW YORK, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to devel...

2 months ago - GlobeNewsWire

Cellectis Announces Participation in Four Upcoming Investor Conferences in September

NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...

3 months ago - GlobeNewsWire

Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors

Former Novartis Veteran Brings Deep Expertise in Drug Development and Commercialization CAMBRIDGE, Mass. , Sept. 1, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-sta...

Other symbols: HGENOMGA
3 months ago - PRNewsWire

Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022

IND clearance received from FDA for UCART20x22 for the treatment of Non-Hodgkin Lymphoma

4 months ago - GlobeNewsWire

Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment ...

NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develo...

4 months ago - GlobeNewsWire

Cellectis to Report Second Quarter 2022 Financial Results

NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving ce...

4 months ago - GlobeNewsWire

Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells ...

NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develo...

5 months ago - GlobeNewsWire

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Dire...

NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develo...

5 months ago - GlobeNewsWire

Cellectis S.A. Reports Results from Annual Shareholders' General Meeting Held on June 28, 2022

NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders' General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 28, 2022 at its head office in Paris, France.

5 months ago - GlobeNewsWire

Cellectis' Annual Shareholders' General Meeting to be Held on June 28, 2022

NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell...

6 months ago - GlobeNewsWire

Why Cellectis' Shares Rose 22.7% This Week

The company bucked the recent downward trend for biotech companies.

6 months ago - The Motley Fool

Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT

NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop...

6 months ago - GlobeNewsWire

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022

◦   UCART20x22 preclinical data presented at AACR demonstrated PoC  with robust in vitro and in vivo anti-tumor activity

6 months ago - GlobeNewsWire

Cellectis to Report First Quarter 2022 Financial Results

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop...

7 months ago - GlobeNewsWire

Calyxt, Inc., Cellectis' Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Cellectis S.A. (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-savin...

7 months ago - GlobeNewsWire

Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics

NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...

7 months ago - GlobeNewsWire

Cellectis Presents Preclinical Data from its First Allogeneic Dual CAR T-cell Product Candidate UCART20x22 for Patien...

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to devel...

8 months ago - GlobeNewsWire

Cellectis to Participate in Two Upcoming Investor Conferences in March

NEW YORK, March 11, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to devel...

8 months ago - GlobeNewsWire